Welcome to our dedicated page for Repligen SEC filings (Ticker: RGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Repligen Corporation (NASDAQ: RGEN), a global life sciences company focused on bioprocessing technologies and systems for manufacturing biological drugs. As a Nasdaq-listed issuer, Repligen submits a range of regulatory documents that give detailed insight into its financial performance, governance and material events.
Among the key filings available are Form 10-K annual reports and Form 10-Q quarterly reports, which typically include audited or reviewed financial statements, management’s discussion and analysis, and information on Repligen’s bioprocessing focus areas: Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. These filings expand on the themes highlighted in the company’s earnings press releases and non-GAAP reconciliations.
Repligen also files Form 8-K current reports to disclose material events. Recent examples include 8-K filings referencing the release of second and third quarter 2025 financial results, as well as an 8-K describing the appointment of a Chief Accounting Officer to enhance the company’s financial reporting infrastructure and Sarbanes–Oxley oversight. Such filings can provide timely context on leadership changes, compensation decisions and other corporate developments.
Investors may also review proxy statements and, where applicable, Form 4 insider transaction reports to understand equity-based compensation and share activity by directors and officers. Together, these documents form the regulatory record of Repligen’s operations as a public company.
On Stock Titan, Repligen’s filings are updated as they are released on EDGAR, with AI-powered summaries that highlight key points from lengthy reports. This helps readers quickly identify major financial trends, governance changes and disclosures related to Repligen’s role as a life sciences and bioprocessing technology company.
Repligen Corporation is soliciting proxies for its 2026 Annual Meeting, where shareholders will vote on three items: electing nine directors, ratifying Ernst & Young LLP as independent auditor for 2026, and approving a non-binding advisory vote on executive compensation.
The board is largely independent, with an independent Chair, fully independent key committees, proxy access rights, majority voting in uncontested elections, and stock ownership guidelines plus anti-hedging and anti-pledging policies. In 2025, Repligen reports 16% revenue growth on a reported and organic non‑COVID basis, driven mainly by consumables and cross‑selling to large biopharma and CDMO customers.
Adjusted operating margin reached 13.8% in 2025, up 0.9 percentage points, and adjusted gross margin expanded by about 2.2 percentage points. However, 2023 PSUs tied to 2023‑2025 Base Organic Revenue Growth and Adjusted ROIC paid out at 0%, reflecting 2.6% revenue growth and 4.4% Adjusted ROIC versus higher targets. CEO Olivier Loeillot’s 2025 total compensation was $6.1 million. As of March 16, 2026, Repligen had 56,399,274 shares outstanding, with the top institutional holders each owning over 5%.
The Vanguard Group filed Amendment No. 7 to Schedule 13G/A reporting no beneficial ownership of Repligen Corp common stock. The filing states 0 shares beneficially owned, representing 0% of the class, and shows zero voting and dispositive power. The amendment notes an internal realignment on January 12, 2026 that led certain Vanguard subsidiaries to report ownership separately.
The filing lists Vanguard’s principal office at 100 Vanguard Blvd., Malvern, PA and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Repligen Corporation Senior VP of R&D Ralf Kuriyel received new equity awards in the form of stock options and restricted stock units. He was granted 5,669 stock options to buy Common Stock at an exercise price of $141.91 per share, expiring on March 5, 2036. One third of these options will vest and become exercisable on each of March 5, 2027, March 5, 2028, and March 5, 2029. He also received 5,284 restricted stock units, each representing one share of Common Stock, vesting in equal annual installments over three years starting on the first anniversary of the grant date. After the restricted stock unit grant, his direct Common Stock holdings increased to 20,062 shares.
Repligen Corporation Chief Executive Officer Olivier Loeillot received new equity awards that increase his direct ownership stake. He was granted 25,890 stock options to buy Common Stock at an exercise price of $141.91 per share, expiring in 2036, vesting in three equal annual installments on March 5, 2027, 2028 and 2029. He also received 24,134 restricted stock units, each representing one share of Common Stock, vesting in equal annual installments over three years beginning on the first anniversary of the grant date. Following these awards, his direct Common Stock holdings total 58,078 shares, and the restricted stock units will be settled only in shares when they vest.
Repligen Corporation’s Chief Operating Officer James Bylund received new equity awards. He was granted stock options for 8,315 shares of Common Stock at an exercise price of $141.91 per share, expiring on March 5, 2036, vesting in three equal annual installments on March 5, 2027, March 5, 2028, and March 5, 2029. He was also awarded 7,751 restricted stock units, each representing one share of Common Stock, vesting in equal annual installments over three years starting on the first anniversary of the grant date. Following these grants, he holds 25,423 Common Stock shares directly.
Repligen Corporation CFO Jason K. Garland reported equity compensation awards consisting of stock options and restricted stock units. He received 8,315 stock options with an exercise price of $141.91 per share, expiring on March 5, 2036, which vest in three equal annual installments on March 5, 2027, March 5, 2028, and March 5, 2029. He was also granted 7,751 restricted stock units, vesting in equal annual installments over three years beginning on the first anniversary of the grant date, each unit representing one share of common stock. Following the award, his direct common stock holdings total 20,092 shares.
Repligen Corp Chief Operating Officer James Bylund reported routine equity compensation activity. He acquired 125 shares of common stock at no cost upon the release of a Performance Stock Unit award tied to pre-established performance criteria, and 62 shares were withheld to cover related tax obligations. After these transactions, he directly holds 17,672 common shares.
Repligen Corp Senior VP R&D Ralf Kuriyel reported equity compensation activity involving common stock. He acquired 125 shares at no cost upon vesting of a previously granted performance stock unit award, after the company met pre-set performance goals. To cover related tax obligations, 42 shares were disposed of and withheld by the company, leaving him with 14,778 directly owned shares.
Repligen Corporation’s Chief Operating Officer James Bylund reported two share dispositions that were automatically used to cover taxes on vesting stock awards, rather than open-market sales. On February 27, 2026, 1,478 common shares at $128.73 per share were withheld, and on March 2, 2026, 2,433 shares at $124.97 per share were withheld.
These shares were retained by the company to satisfy Bylund’s tax withholding obligations triggered by the release of restricted stock units. After the March 2 withholding, Bylund directly owned 17,609 Repligen common shares.
Repligen Corp Chief Executive Officer Olivier Loeillot reported two Form 4 transactions where shares were withheld to cover taxes on restricted stock units. On February 27, 2026, 344 shares of common stock were disposed of at $128.73 per share, leaving 35,554 shares directly owned. On March 2, 2026, 1,610 shares were disposed of at $124.97 per share, leaving 33,944 shares directly owned. These are tax-withholding dispositions, not open-market sales.